PUBLISHER: The Business Research Company | PRODUCT CODE: 1764264
PUBLISHER: The Business Research Company | PRODUCT CODE: 1764264
Blepharitis is a common eye disorder characterized by inflammation of the eyelids, typically at the base of the eyelashes. It often leads to symptoms such as redness, itching, crusting, and a gritty or burning feeling in the eyes. This condition is usually chronic and may be caused by bacterial infections, skin disorders like dandruff, or blocked oil glands.
The primary types of blepharitis include anterior blepharitis, posterior blepharitis, and mixed blepharitis. Anterior blepharitis affects the front edge of the eyelid, where the eyelashes grow. Treatment options commonly include eye cleansers, artificial tears, and antibiotic therapy. Diagnosis methods such as physical examinations and comprehensive eye evaluations are employed across various healthcare settings, including hospitals and specialty clinics.
The blepharitis market research report is one of a series of new reports from The Business Research Company that provides blepharitis market statistics, including blepharitis industry global market size, regional shares, competitors with a blepharitis market share, blepharitis market segments, market trends and opportunities, and any further data you may need to thrive in the blepharitis industry. This blepharitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The blepharitis market size has grown strongly in recent years. It will grow from $0.86 billion in 2024 to $0.97 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period can be attributed to the rise in eye-related disorders, an aging global population, heightened awareness of ocular hygiene, increased screen time, and a surge in allergic and dermatological conditions.
The blepharitis market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to the advancement of personalized treatment approaches, a growing preference for convenient at-home care options, increased patient awareness, expansion into emerging markets, and streamlined regulatory approvals. Key trends expected during this period include the emergence of innovative treatments such as intense pulsed light therapy, AI-powered diagnostic imaging, automated eyelid imaging systems, multi-modal treatment strategies, and the development of biologic drugs.
The growing awareness of eye care is expected to drive the expansion of the blepharitis market in the coming years. Eye care encompasses a variety of services, treatments, and practices designed to preserve and enhance eye health and vision. Increased awareness is essential, as good vision plays a critical role in an individual's independence, educational achievement, work productivity, and overall quality of life. Unaddressed vision problems can negatively impact daily functioning, academic performance, and job efficiency. Managing blepharitis contributes to comprehensive eye care by promoting early detection of symptoms, encouraging consistent eyelid hygiene, and preventing complications such as dry eye and styes through timely treatment. For example, in October 2024, the Association of Optometrists (AOP), a UK-based organization, reported that the number of individuals living with sight loss in the UK is projected to rise to approximately 2.8 million by 2035-a 27% increase compared to 2022. Therefore, increasing awareness around eye care is significantly contributing to the growth of the blepharitis market.
Leading companies in the blepharitis market are emphasizing the development of novel therapies, including targeted anti-parasitic agents and innovative ophthalmic formulations, to strengthen their competitive position. Innovative ophthalmic formulations involve advanced drug delivery systems and compositions designed to enhance treatment efficacy, safety, and patient comfort in managing eye disorders. For example, in July 2023, Tarsus Pharmaceuticals Inc., a US-based biopharmaceutical company, received FDA approval for XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Previously known as TP-03, XDEMVY is the first and only FDA-approved therapy that directly targets Demodex mites-the underlying cause of Demodex blepharitis. The approval was supported by robust clinical data from two pivotal trials (Saturn-1 and Saturn-2) involving 833 patients, demonstrating notable symptom improvement and a higher rate of complete collarette cure compared to placebo. The recommended dosage is one drop in each eye twice daily for six weeks. XDEMVY is generally well tolerated, with mild stinging or burning being the most commonly reported side effects.
In July 2023, LianBio, a US-based biotechnology company, entered into a partnership with Tarsus Pharmaceuticals to broaden access to XDEMVY for the treatment of Demodex blepharitis and meibomian gland disease in regions with substantial unmet medical needs. The collaboration aims to leverage strong clinical evidence and address the large patient population requiring effective treatment options. Tarsus Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing innovative therapies, with a strong focus on eye care.
Major players in the blepharitis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Thea Pharmaceuticals Ltd, Harrow Inc., URSAPHARM Arzneimittel GmbH, Tarsus Pharmaceuticals Inc., Scope Ophthalmic Ltd, Santen Pharmaceutical Co Ltd., NovaBay Pharmaceuticals Inc., InSite Vision Incorporated, MiBo Medical Group, and Nicox SA.
North America was the largest region in the blepharitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blepharitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the blepharitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The blepharitis market consists of revenues earned by entities by providing services such as antibiotic therapy, topical corticosteroids, topical and oral antibiotics, ointments, and eye cleansers. The market value includes the value of related goods sold by the service provider or included within the service offering. The blepharitis market also includes sales of steroid eye drops, ointments, eyelid cleansers, lid scrubs, and warm compress masks. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Blepharitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on blepharitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for blepharitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blepharitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.